Mitochondrial Complex Iii is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Mitochondrial Complex III (Cytochrome bc1 Complex or Ubiquinol-Cytochrome c Reductase) is a central component of the Electron Transport Chain (ETC). It catalyzes the transfer of electrons from ubiquinol (CoQH2) to cytochrome c while simultaneously pumping protons across the inner mitochondrial membrane, contributing to the establishment of the proton gradient that drives ATP synthesis. [@zhang1998]
Complex III (Cytochrome bc1) Pathway
flowchart TD
A["Ubiquinol<br/>CoQH2 -> BComplex III<br/>Cytochrome bc1"]
subgraph Q_Cycle
B --> C["First Electron<br/>to Cytochrome c"]
C --> D["Second Electron<br/>to Ubiquinone"]
D --> E["Ubiquinol<br/>Regenerated"]
end
E --> A
B --> F["Cytochrome c<br/>Reduced"]
F --> G["Complex IV"]
H["Protons H+ --> IIntermembrane<br/>Space"]
B -->|"Pump H+"| I
style A fill:#1a0a1f,stroke:#333,color:#e0e0e0
style F fill:#3a3000,stroke:#333,color:#e0e0e0
style I fill:#9f9,stroke:#333,color:#0d0d1a
Overview
...
Mitochondrial Complex III
Introduction
Mitochondrial Complex Iii is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Mitochondrial Complex III (Cytochrome bc1 Complex or Ubiquinol-Cytochrome c Reductase) is a central component of the Electron Transport Chain (ETC). It catalyzes the transfer of electrons from ubiquinol (CoQH2) to cytochrome c while simultaneously pumping protons across the inner mitochondrial membrane, contributing to the establishment of the proton gradient that drives ATP synthesis. [@zhang1998]
Complex III (Cytochrome bc1) Pathway
Mermaid diagram (expand to render)
Overview
Complex III occupies a critical position in the ETC, receiving electrons from Complex I and Complex II via ubiquinol and transferring them to cytochrome c, which then carries them to Complex IV. This electron transfer is coupled with proton pumping, making Complex III essential for cellular energy production. Dysfunction of Complex III has been implicated in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and MELAS syndrome. [@hunte2000]
Structure
Complex III is a symmetric dimer, with each monomer containing 11 subunits that work together to catalyze electron transfer and proton pumping: [@rich2010]
Core Catalytic Subunits
Cytochrome b: The largest subunit, containing two heme b groups (bL and bH) that serve as electron acceptors. The low-potential heme bL and high-potential heme bH are positioned on opposite sides of the inner membrane.
Rieske Iron-Sulfur Protein (ISP, UCRF1): Contains a 2Fe-2S cluster that undergoes redox changes during electron transfer. The ISP has a mobile head domain that shuttles between cytochrome c1 and cytochrome b.
Cytochrome c1: A heme-containing protein that receives electrons from the ISP and passes them to cytochrome c.
Additional Subunits
Core protein 1 (UQCRFS1): Part of the core matrix arm
Superoxide dismutase 1 (SOD1): Associated with the complex
Other small subunits: Provide structural stability
Function
Q Cycle Mechanism
The Q cycle is the fundamental mechanism by which Complex III transfers electrons and pumps protons: [@sazanov2013]
First ubiquinol oxidation: The first ubiquinol (CoQH2) binds to the Qo site. It donates one electron to the 2Fe-2S cluster of the ISP and one electron to heme bL. The ISP then passes its electron to cytochrome c1 and subsequently to cytochrome c. The two protons released from ubiquinol are pumped across the inner membrane.
Second ubiquinol oxidation: A second ubiquinol binds to the Qo site. One electron goes through the same ISP-cytochrome c1 pathway to cytochrome c. The other electron goes to heme bL, then to heme bH, and finally reduces ubiquinone (CoQ) to ubiquinol at the Qi site.
This elegant mechanism allows Complex III to pump four protons per pair of electrons transferred while also regenerating ubiquinol for continued electron flow. [@castellani2002]
Proton Pumping
Stoichiometry: 4 protons pumped per electron pair (2 protons per ubiquinol oxidized)
Proton motive force: The proton gradient created drives ATP synthase (Complex V)
Coupling efficiency: Critical for maintaining cellular energy homeostasis
Electron Transfer Pathway
The sequential electron transfer within Complex III follows this path: [@parker1990] Ubiquinol → 2Fe-2S → Cytochrome c1 → Cytochrome c ↓ Heme bL → Heme bH → Ubiquinone
Regulation
Post-Transcriptional Regulation
Phosphorylation: Multiple phosphorylation sites modulate Complex III activity
Acetylation: Metabolic status affects acetylation levels of core subunits
Quality Control
Assembly factors: Specialized proteins assist in complex formation
Turnover: Damaged Complex III components are degraded and replaced
Neurodegeneration Relevance
Alzheimer's Disease (AD)
Complex III dysfunction in AD contributes to disease pathogenesis through multiple mechanisms: [@lin2006]
Electron leak and ROS generation: Impaired electron flow leads to increased superoxide production at the Qo site
Amyloid-beta interaction: Aβ binds to Complex III, inhibiting its activity and enhancing ROS production
Mitochondrial dynamics disruption: Complex III dysfunction affects mitochondrial fission/fusion balance
Bioenergetic failure: Reduced ATP production contributes to synaptic dysfunction and neuronal death
Tau pathology relationship: Hyperphosphorylated tau affects mitochondrial transport and function
Evidence: Post-mortem studies show reduced Complex III activity in AD brains, particularly in the hippocampus and temporal cortex. Cytochrome b mutations have been associated with early-onset AD in some families. [@schapira1998]
Parkinson's Disease (PD)
Complex III plays a complex role in PD pathophysiology: [@wallace1999]
Complex I deficiency compensation: Reduced Complex I activity may increase reliance on Complex III
α-Synuclein interaction: α-Synuclein oligomers can bind to mitochondrial Complex III, impairing its function
LRRK2 mutations: G2019S LRRK2 affects mitochondrial function including Complex III activity
PINK1/Parkin pathway: Impaired mitophagy leads to accumulation of dysfunctional Complex III
Evidence: While Complex I deficiency is the most well-established mitochondrial defect in PD, Complex III dysfunction also contributes to dopaminergic neuron vulnerability. [@finsterer2007]
MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes)
mtDNA mutations: A3243G and other mtDNA mutations in the cytochrome b gene impair Complex III assembly and function
Heteroplasmy: The percentage of mutated mtDNA determines disease severity
Energy failure: Reduced Complex III activity causes severe ATP depletion
Lactic acidosis: Impaired oxidative phosphorylation leads to glycolytic compensation and lactic acidosis
Stroke-like episodes: Mitochondrial dysfunction in endothelial cells contributes to vascular dysfunction
Amyotrophic Lateral Sclerosis (ALS)
SOD1 mutations: Mutant SOD1 can impair Complex III function
Energy metabolism: Motor neurons are particularly vulnerable to Complex III dysfunction due to their high energy demands
Oxidative stress: Complex III dysfunction increases ROS, contributing to motor neuron degeneration
Huntington's Disease (HD)
Mutant HTT effects: Huntingtin protein affects mitochondrial Complex III function
Energy deficits: Reduced Complex III activity contributes to striatal neuron vulnerability
Oxidative damage: Increased ROS from Complex III dysfunction
Therapeutic Implications
Potential Therapeutic Strategies
CoQ10 supplementation: Can improve electron transfer and bypass some Complex III defects
The study of Mitochondrial Complex Iii has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [@thambisetty2007]
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
[Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
[Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
[Stoolman JS et al., Nat Metab (2024 Aug)](https://pubmed.ncbi.nlm.nih.gov/39048801/)
[Chang JC et al., Cells (2025 Jul 25)](https://pubmed.ncbi.nlm.nih.gov/40801581/)
[Niño SA et al., Biochim Biophys Acta Mol Basis Dis (2026 Mar 3)](https://pubmed.ncbi.nlm.nih.gov/41785939/)
[Huayta J et al., bioRxiv (2025 Oct 23)](https://pubmed.ncbi.nlm.nih.gov/41278705/)
[Zhang J et al., Mol Neurobiol (2025 Oct)](https://pubmed.ncbi.nlm.nih.gov/40588669/)
References
Trumpower BL, The protonmotive Q cycle (1990)
Zhang Z, Huang L, Shulmeister VM, Kim YW, Berry EA, Electron transfer by domain movement in cytochrome bc1 (1998)
Hunte C, Koepke J, Lange C, Roßmanith T, Michel H, Structure at 2.3 Å resolution of the cytochrome bc1 complex from the yeast Saccharomyces cerevisiae (2000)
Unknown, Rich PR, Maréchal A. The mitochondrial respiratory chain (2010)
Sazanov LA, A giant molecular proton pump in the respiratory chain (2013)
Castellani R, Hirai K, Aliev G, et al, Role of mitochondrial dysfunction in Alzheimer's disease (2002)
Parker WD Jr, Filley CM, Parks JK, Complex I deficiency in Alzheimer's disease frontal cortex (1990)
Lin MT, Beal MF, Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases (2006)
Schapira AH, Mitochondrial involvement in Parkinson's disease (1998)
Wallace DC, Mitochondrial diseases in man and mouse (1999)
Finsterer J, Hematological manifestations of primary mitochondrial disorders (2007)
Thambisetty M, Newman NJ, Measurement of mitochondrial cytochrome bc1 complex activity in skeletal muscle (2007)